Número 3 - EII al día

erts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van DeventerSJ. Infliximab maintenance therapy for fistulizing Crohn’s disease. NEngl J Med 2004; 350: 876–85.16. Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-termtreatment of rectovaginal fistulas in Crohn's disease: response to infliximabin the ACCENT II Study. Clin Gastroenterol Hepatol. 2004 Oct; 2(10): 912-20.17. Parsi MA, Lashner BA, Achkar JP, Connor JT, Brzezinski A. Type of fistuladetermines response to infliximab in patients with fistulous Crohn's disease.Am J Gastroenterol 2004; 99: 445-9.18. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntoshD, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab)in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130: 323-33.19. Colombel J, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Remo P, etal. Adalimumab induces and maintains clinical response and remission inpatients with active Crohn's disease: results of the CHARM trial. Gastroenterology2007; 132: 52-65.20. Sandborn WJ, Hanauer SB, Rutgeers PJ y cols. Adalimumab for manteinancetreatment of Crohn’s disease: results of the CLASSIC II trial. Gut2007 doi:10.1136/gut.2006.106781.21. Schreiber S, Rutgeerts P, Fedorak R y cols. A randomized, placebo controlledtrial of Certolizumab pegol (CDP870) for treatment of Crohn´s disease.Gastroenterology 19995; 129: 807-18.22. Sandborn WJ, Feagan BG, Stoinov S y cols. Certolizumab pegol for thetreatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.23. Schreiber S, Khaliq-Kareemi M, Lawrance I, Hanauer S, McColm J, BloomfieldR, Sandborn W. Maintenance therapy with Certolizumab pegolfor Crohn’s disease. N Engl J Med 2007; 357: 239-50.24. Sandborn WJ, Rutgeerts P, Enns RA, Hanauer SB, Colombel JF, PanaccioneR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn’s diseasepatients previously treated with infliximab therapy: a randomizedtrial. Ann Intern Med 2007; 146: 829-38.25. Hinojosa J, Gomollón F, García S y cols. Efficacy and safety of short-termadalimumab treatment in patients whit active Crohn´s disease who lostresponse or showed intolerance to infliximab: a prospective open-label,multicentre trial. Aliment Pharmacol Ther 2007; 25: 409-18.26. Sandbron WJ, Hanuer S, Loftus EV Jr y cols. An opel-label study of thehuman anti TNF monoclonal antibody adalimumab in subjects with priorloss of response or intolerance to infliximab in Crohn´s disease. Am J Gastreoenterol2004; 99: 1984-99.27. Papadakis KA, Shaye OA, Vasiliauskas EA y cols. Safety and efficacy ofadalimumab (D2E7) in Crohn´s disease patients with attenuated responseto infliximab. Am J Gastroenterol 2005; 100: 75-9.28. Anwar M, O´Sullivan M, Ryan B y cols. An open label study of adalimumabin Crohn´s disease patients with a loss of response to infliximab. Gastroenteroloy2006; 130 (Supll 4): A62.29. S. Vermiere, MT Abreu, GD H´aens. Assesment of certolizumab pegol inthe treatment of Crohn´s disease in patients for whom infliximab treatmentwas not successful: open label preliminary results from the WEL-COME study. Oral presentation ECCO Congress, Lyon, febrero 2008.30. Colombel JF, Loftus EV, Jr., Tremaine WJ, Egan LJ, Harmsen WS, SchleckCD, et al. The safety profile of infliximab in patients with Crohn's disease:the Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.31. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, ChenDM, Pritchard ML, Sandborn WJ. Serious infections and mortality in associationwith therapies for Crohn’s disease: TREAT registry. Clin GastroenterolHepatol 2006; 4: 621–30.32. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL,Montori V.Anti-TNF antibody therapy in rheumatoid arthritis and the risk of seriousinfections and malignancies: systematic review and meta-analysis of rareharmful effects in randomized controlled trials. JAMA 2006; 295:2275–85.33. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-celllymphoma in adolescents and young adults with Crohn's disease: a cautionarytale?. Inflamm Bowel Dis 2007; 13: 1024-30.34. Miller DH, Khan OA, Sheremata Wa, Blumhardt LD, Rice GP, Libonati MA,et al. A controlled trial of natalizumab for relapsing multiple sclerosis. NEng J Med 2003; 348: 15-23.35. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, RutgeertsP, et al. Natalizumab for active Crohn´s disease. N Eng J Med 2003; 348:24-32.36. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenancetherapy for Crohn´s disease. N Eng J Med 2005; 353 (18): 1912-25.37. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressivemultifocal leukoencephalopathy in a patient treated with natalizumab.NEngl J Med. 2005 Jul 28; 353(4): 375-8138. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al.Evaluation of patients treated with natalizumab for progressive multifocalleukoencephalopathy. N Eng J Med 2006; 354: 924-33.39. Julián Panés, Fernando Gomollón, Carlos Taxonera, Joaquin Hinojosa, JuanClofent and Pilar Nos. Crohn’s Disease; a Review of Current Treatmentwith a Focus on Biologics. Drugs 2007; 67 (17): 2511-37.40. American Gastroenterological Association institute technical review oncorticosteroids, inmunomodulators and infliximab in inflammatory boweldisease. Gastroenterology 2006; 130: 940-87.41. D´Haens G, Baert F, van Assche G: Early combined immunosuppression orconventional management in patients with newly diagnosed Crohn´s disease:an open randomised trial. Lancet 2008; 371: 660-6742. Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, SandsBE. Crohn's disease patients' risk-benefit preferences: serious adverse eventrisks versus treatment efficacy. Gastroenterology. 2007; 133: 769-79.43. S. Vermeire, G. Van Assche, P. Rutgeerts. Review article: altering the naturalhistory of evidence for and against current therapies. Aliment PharmacolTher 2007; 25: 3-12.162 • Enfermedad Inflamatoria Intestinal al día - Vol. 7 - Nº. 2 - 2008